Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Tallantyre

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Neurology|February 21, 2013
Autism and intellectual disabilityE Tallantyre, Neil P Robertson
Journal of Neurology|May 8, 2023
Optic neuritis and MOGADZ M Htet, E Tallantyre
International MS Journal|September 11, 2008
Spotlight on teriflunomideE Tallantyre, N Evangelou, C S Constantinescu
Journal of Neurology|March 14, 2022
Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapiesM Allman, E Tallantyre, N P Robertson
Journal of Neurology|January 23, 2021
KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosisKelly Hares, K Kemp, S Loveless, et al.
Multiple Sclerosis and Related Disorders|September 11, 2022
Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapiesR Beesley, M Cauchi, L Davies, et al.
Multiple Sclerosis and Related Disorders|October 6, 2024
The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosisE Coerver, L Schoof, L Hogenboom, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Neurology|February 21, 2013
Autism and intellectual disabilityE Tallantyre, Neil P Robertson
Journal of Neurology|May 8, 2023
Optic neuritis and MOGADZ M Htet, E Tallantyre
International MS Journal|September 11, 2008
Spotlight on teriflunomideE Tallantyre, N Evangelou, C S Constantinescu
Journal of Neurology|March 14, 2022
Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapiesM Allman, E Tallantyre, N P Robertson
Journal of Neurology|January 23, 2021
KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosisKelly Hares, K Kemp, S Loveless, et al.
Multiple Sclerosis and Related Disorders|September 11, 2022
Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapiesR Beesley, M Cauchi, L Davies, et al.
Multiple Sclerosis and Related Disorders|October 6, 2024
The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosisE Coerver, L Schoof, L Hogenboom, et al.
Pageof 1